- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Cybin is operational in Ireland, following its successful product launches and regulatory approvals in various global markets.
1 report, 1 independent
Updated Sep 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cybin is operational in Ireland, following its successful product launches and regulatory approvals in various global markets.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Cybin develops treatments for GAD and receives European authorities approval for a Phase 3 trial, which will enroll participants in Australia.Sub-event
Cybin is operational in Ireland as part of its global market expansion.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
-
Cybin
Canadian pharmaceutical company
Coverage
Newest first; wire copies grouped- Business WireCybin to Participate in the Cantor Global Healthcare Conference 2025 TORONTO, September 03, 2025--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinica